| Product | Ideal for | Price from | Free version | |
|---|---|---|---|---|
| Broad preclinical safety and discovery services | See website | No | Visit | |
| Integrated preclinical and clinical development | See website | No | Visit | |
| Integrated discovery and preclinical platform | See website | No | Visit | |
| Bioanalysis and device testing | See website | No | Visit | |
| Full service CRO with preclinical support | See website | No | Visit | |
| Regulatory and development consulting | See website | No | Visit | |
| Preclinical and clinical development | See website | No | Visit | |
| Integrated biopharma development | See website | No | Visit |
Preclinical contract research organizations run the safety, toxicology and pharmacology studies that support a drug or device before human trials. Sponsors judge them on scientific quality, GLP compliance, timelines and communication, not on marketing claims. The firms below are among the most reviewed and most used in the field.

Ideal for: Broad preclinical safety and discovery services

Charles River Laboratories is the largest dedicated preclinical CRO, with services spanning safety assessment, toxicology, pathology, bioanalysis and research models. Its global facilities and deep scientific staff make it a default choice for sponsors who need a complex IND enabling program run to GLP standards.
Pricing reflects its scale, and timelines depend on study type and facility capacity, so book early for large programs. For a sponsor that wants breadth, regulatory experience and a single partner for most preclinical work, Charles River is the leading choice in this list.

Ideal for: Integrated preclinical and clinical development

Labcorp Drug Development, formerly Covance, offers preclinical services including toxicology, safety pharmacology and bioanalysis, integrated with clinical development. That integration helps sponsors who want continuity from preclinical studies into early clinical trials, with shared data and teams.
As a large organization, navigation can feel complex, and pricing is project based. For a sponsor planning a program that spans preclinical into clinical, Labcorp offers a coherent path and strong bioanalytical depth.

Ideal for: Integrated discovery and preclinical platform

WuXi AppTec provides an integrated platform covering discovery, preclinical development, safety assessment and manufacturing support, with facilities across Asia, North America and Europe. Its breadth appeals to biotech sponsors that want one partner from early discovery through IND enabling studies.
Some sponsors weigh geopolitical and supply chain factors when choosing a global CRO, so assess those risks for your program. Pricing varies by project. For an integrated, cost competitive preclinical program, WuXi AppTec is a strong contender.

Ideal for: Bioanalysis and device testing
Eurofins Scientific operates a vast laboratory network, with preclinical services including safety testing, bioanalysis, biomarker work and medical device biocompatibility. Its device expertise is a particular strength for sponsors whose product is a device or combination product.
Preclinical scope is narrower than a dedicated giant such as Charles River, so sponsors needing full toxicology programs may use Eurofins for specific studies. For bioanalysis and device testing, Eurofins is a reliable and well reviewed choice.
Ideal for: Full service CRO with preclinical support
ICON is a large full service CRO best known for clinical work, but it also offers preclinical and laboratory services supporting early development. Its scale and global reach suit sponsors who want a partner that can carry a program from preclinical into late phase trials.
Preclinical is one part of a larger clinical business, so sponsors needing deep dedicated toxicology capacity should compare ICON with Charles River for that specific work. For a sponsor valuing a single long term CRO partner, ICON is a credible option.

Ideal for: Regulatory and development consulting
Parexel offers drug development services with a strong regulatory and consulting focus, plus preclinical support through its broader development capabilities. Sponsors value its regulatory strategy help when planning IND enabling programs and agency interactions.
Direct preclinical laboratory capacity is lighter than dedicated toxicology CROs, so Parexel often partners or focuses on strategy and oversight. For a sponsor that needs regulatory guidance alongside preclinical work, Parexel is a strong advisory partner.

Ideal for: Preclinical and clinical development
PPD, part of Thermo Fisher Scientific, provides drug development services including laboratory, safety assessment and clinical support. Its backing by Thermo Fisher gives it scale in laboratories and supplies, and its global facilities cover many therapeutic areas.
As a large organization, preclinical focus varies by site, so check the specific facility and team for your study. For a sponsor that wants a large, stable CRO with laboratory depth, PPD is a solid choice, especially when a program may extend into clinical phases.

Ideal for: Integrated biopharma development
Syneos Health combines clinical development with commercial services, and offers preclinical support as part of integrated biopharma programs. Its therapeutic expertise and integrated model suit sponsors who want development and commercial thinking together from an early stage.
Direct preclinical laboratory capacity is lighter than dedicated toxicology firms, so sponsors with large safety programs should verify capacity for their specific studies. For an integrated development partner with commercial insight, Syneos Health is a respected option.
We compared official service pages, industry reports and public reviews for each firm, focusing on CROs that are still operating and serve sponsors in October 2026. We favored firms with GLP compliant facilities, broad preclinical services, and a record of regulatory submissions. We left out firms with no verifiable preclinical facilities, firms under serious regulatory sanction, and firms that only offered clinical services. Prices are project based, so request proposals for your exact study design.
Start with your study design and therapeutic area. A CRO with deep experience in your modality, whether small molecule, biologic or device, will design better studies and anticipate regulatory questions. Ask for examples of similar programs, not just general capabilities.
Next, audit the facility. Visit in person or commission an audit, review GLP compliance history, inspect animal welfare practices, and meet the study director and pathologist who would run your study. A polished sales presentation tells you little; a facility audit tells you a lot.
Finally, compare proposals on science, not just price. Check timelines, study design quality, reporting standards, communication plans and change order policies. The cheapest proposal often costs more when a study must be repeated or a regulatory question delays your program. Choose the CRO you trust to run the study right the first time.
Communication cadence is worth agreeing in writing before a study starts. Decide how often you receive updates, who your day to day contacts are, and how quickly the CRO responds to questions or protocol issues. Studies run for months, and a CRO that communicates well during setup usually communicates well during problems, while one that goes quiet early rarely improves. Put reporting milestones and escalation contacts in the contract, not just in a sales conversation. Also plan for data ownership and transfer from the start. Confirm that raw data, pathology slides, and study records transfer to you on a defined schedule, and in formats your team and future partners can use. A study that ends with data locked in a vendor system creates delays when you need it for a regulatory filing or a follow on study. Data transfer terms belong in the initial agreement, when you still have room to negotiate them.
Animal welfare standards deserve direct questions during any CRO evaluation, since they reflect scientific quality as well as ethics. Ask about accreditation, veterinary oversight, enrichment programs, and how the facility reports welfare issues to sponsors. A CRO that answers openly and welcomes welfare questions is usually one that runs careful science, since good welfare and good data go together. Sponsors increasingly face questions about welfare from investors and the public, so this is both an ethical and a reputational matter.
Charles River Laboratories is the leading dedicated preclinical CRO for breadth and regulatory experience. Labcorp and WuXi AppTec are strong integrated alternatives. The best choice depends on your modality, study type and timeline.
Costs vary widely by study type, species, duration and complexity, and CROs quote per project. A small pilot study costs far less than a full GLP toxicology program. Request detailed proposals with study design, timelines and change order terms.
Good Laboratory Practice is a quality system for nonclinical safety studies, covering facilities, personnel, procedures and records. Regulators require GLP compliance for safety studies supporting drug approval, so confirm any CRO you use is GLP compliant for your study type.
Timelines range from weeks for early screening to many months for GLP toxicology and safety pharmacology programs. Facility capacity, study design and regulatory questions all affect timing, so confirm a realistic schedule in the proposal.
Yes, always audit the facility, review regulatory history, and speak to past sponsors. A study failure or regulatory finding can delay a program by months or years, so due diligence before signing is essential.